Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Rating) – Equities researchers at Wedbush issued their Q1 2022 EPS estimates for shares of Black Diamond Therapeutics in a research report issued on Tuesday, March 29th. Wedbush analyst R. Driscoll anticipates that the company will post earnings per share of ($0.77) for the quarter. Wedbush currently has […]
Black Diamond Therapeutics (NASDAQ:BDTX – Get Rating) was downgraded by equities researchers at Wedbush from an “outperform” rating to a “neutral” rating in a report issued on Tuesday, Briefing.com reports. A number of other analysts also recently weighed in on the stock. Stifel Nicolaus reduced their target price on shares of Black Diamond Therapeutics from […]
Black Diamond Therapeutics (NASDAQ:BDTX – Get Rating) was downgraded by HC Wainwright from a “buy” rating to a “neutral” rating in a research note issued on Tuesday, MarketBeat.com reports. Separately, Stifel Nicolaus lowered their price target on shares of Black Diamond Therapeutics from $10.00 to $4.00 and set a “hold” rating for the company in […]
Black Diamond Therapeutics (NASDAQ:BDTX – Get Rating) posted its earnings results on Thursday. The company reported ($0.71) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.00) by $0.29, MarketWatch Earnings reports. Shares of NASDAQ BDTX traded up $0.04 during mid-day trading on Friday, reaching $3.06. The company had a trading volume […]
Geode Capital Management LLC lowered its stake in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Rating) by 2.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 349,980 shares of the company’s stock after selling 9,622 shares during the […]